PYPD
PolyPid Ltd. (NASDAQ)
Healthcare — Biotechnology
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Price History
Fundamentals
| Market Cap | $96.83M |
| P/E Ratio (TTM) | - |
| Forward P/E | -4.02 |
| EPS (TTM) | $-1.74 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -758.61% |
| Debt/Equity | 26.69 |
| Recommendation | None |
| Analyst Target | $12.25 |
| Analysts | 4 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 64.0 |
| Beta | 1.43 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $5.24 |
| 52-Week Low | $3.06 |
| 50-Day Avg | $4.67 |
| 200-Day Avg | $4.20 |
| Avg Volume | 115.7K |
| Volume | 186.7K |
Performance Analysis
BULLISHPYPD shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:28 UTC
Back to Screener Export Report